About the research study

COVID-19 research study to inform our decisions

Falck has initiated a research study, testing up to 4,000 employees in Denmark and Sweden to assess the prevalence of COVID-19 antibodies among our employees over a period of six months in the second half of 2020.

In early 2020, COVID-19 appeared in our lives and we realised that it was something that was not going to go away anytime soon. It was something we had to protect ourselves against and learn more about for quite a while.

Data is needed to inform decisions and Falck is in a unique position to provide that. Being a large organisation, spread all over Denmark and Sweden and with different exposure groups, regular testing of employees will lead to valuable data and monitoring of the progression of this pandemic.

We pride ourselves of contributing positively to society and with funding from the Lundbeck Foundation and renowned researchers from Danish hospitals and universities, the project may become an important societal research asset to follow the development of the COVID-19 outbreak and build knowledge that can help us protect employees in the health sector as well as in society.

The value of the research is expected to increase as we get more results over time. We will be able to see how the pandemic evolves over half a year, learn to understand why we see the spread, at which pace and its momentum. The research study will inform us about how we can protect ourselves better, our employees and our surroundings and ensure that we can deliver services to all customers even though there is a risk of COVID-19.

Furthermore, with operations in two countries that have taken different political approaches to the COVID-19 outbreak, we are in a unique position to conduct a cross-border comparative study.

Contact

Research responsible

Jannie Laursen

Email: jannie.laursen@falck.com
Send email

Explore further